Argenica Therapeutics (ASX:AGN) Advances Stroke Drug Program with Clinical Trial Preparations

Anjali Anand

11 August 2026 11:18 PM AEST

Argenica Therapeutics (ASX:AGN) Advances Stroke Drug Program with Clinical Trial Preparations

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Argenica Therapeutics (ASX:AGN) advanced preparations for a late-stage clinical trial targeting moderate to severe acute ischaemic stroke patients.
The company completed three FDA-requested assays related to ARG-007 (xaranetide), including hERG, TNK and genotoxicity assessments.
ARG-007 received the International Nonproprietary Name (INN) xaranetide from the World Health Organisation.
Argenica reported cash reserves of $6.35 million as at 30 June 2026 to support ongoing development activities.
The company is evaluating further development opportunities for xaranetide following preclinical concussion study results.

Argenica Therapeutics Advances ARG-007 Clinical Development Program

Argenica Therapeutics Limited (ASX:AGN) is a clinical-stage biotechnology company focused on developing neuroprotective therapeutics for stroke and other acute neurological injuries. The company’s latest quarterly update for the period ended 30 June 2026 outlined progress across clinical trial preparation, regulatory activities and research programs.

The company is developing ARG-007 (xaranetide), a neuroprotective drug candidate designed to reduce brain tissue damage following acute neurological injuries. During the quarter, Argenica progressed preparations for a targeted late-stage clinical trial in moderate to severe acute ischaemic stroke (AIS) patients.

Late-Stage Stroke Trial Preparations Continue

Argenica completed a Phase 2 clinical trial of ARG-007 in acute ischaemic stroke patients across Australian hospitals during 2025. The company stated that the trial provided safety and efficacy data supporting further development activities for moderate to severe AIS patients.

During the June 2026 quarter, Argenica worked with its global stroke Clinical Advisory Committee to progress the design of a planned late-stage trial. The proposed trial is expected to use patient selection strategies focused on stroke severity and diagnostic tools to support enrolment.

The company is developing the trial design as either a Phase 2b or a seamless Phase 2b/3 trial. Argenica expects to present the clinical trial design and strategy to the market in Q3 CY2026, followed by preparation of a protocol synopsis for submission to the U.S. Food and Drug Administration (FDA) for feedback.

FDA-Requested Safety Assessments Completed

Argenica also provided an update regarding the FDA clinical hold associated with ARG-007 (xaranetide). The FDA had requested additional information relating to ARG-007’s interaction with tenecteplase (TNK), potential cardiac activity effects assessed through a hERG assay, and genotoxicity testing.

During the quarter, the company completed the requested hERG, TNK and genotoxicity assays. Argenica reported that all three assessments demonstrated clean and favourable safety profiles. Following finalisation of the trial protocol, the company intends to submit a response to the FDA clinical hold and seek approval of the Investigational New Drug (IND) application for ARG-007.

Xaranetide Receives International Naming Recognition

During the quarter, the World Health Organisation confirmed the International Nonproprietary Name (INN) xaranetide for ARG-007. The company stated that xaranetide will become the recognised generic name for ARG-007 across regulatory, scientific and medical communities.

The naming milestone relates to the company’s lead neuroprotective drug candidate as it progresses through clinical development activities.

Research Expansion into Traumatic Brain Injury

Following the quarter end, Argenica reported results from a preclinical concussion study evaluating xaranetide. The study showed reductions in secondary injury effects in a repeated mild traumatic brain injury (mTBI) animal model.

The study, conducted by Curtin University, reported that a single low dose of xaranetide administered after repeated mTBI reduced neuroinflammation, oxidative stress and axonal damage. The reported effects lasted up to 11 days following injury.

Based on these findings, Argenica stated that it is considering further steps to advance xaranetide development in this indication.

Cash Position and Quarterly Activities

Argenica reported cash reserves of $6.35 million as at 30 June 2026. The company recorded net operating cash outflows of $1.605 million for the quarter ended 30 June 2026.

Research and development expenditure during the quarter was $0.995 million, including Investment in drug Manufacturing activities for a late-stage AIS trial and payments related to preclinical and non-clinical studies. Staff costs were $0.432 million, while corporate administration costs were $0.199 million.

The company’s Appendix 4C reported cash and cash equivalents of $6.355 million at the end of the quarter, with estimated funding available for approximately four quarters based on the reported operating cash flow.

Argenica Share Market Information

Based on the provided market data, Argenica Therapeutics (ASX:AGN) was trading at $0.180, representing an increase of $0.005 or 2.857%. The company recorded trading Volume of 5,253 shares, with a Market Capitalisation of $22.47M.

The stock traded within a daily range of $0.180 to $0.180, compared with the previous close of $0.175. The provided 52-week trading range was between $0.087 and $0.770.

Argenica has 128,456,712 shares on issue, with ordinary fully paid shares listed on the Australian Securities Exchange.

Looking Ahead

Argenica’s upcoming activities are focused on progressing ARG-007 through late-stage clinical trial preparations, regulatory discussions and additional research programs. The company is continuing work on trial protocol development, manufacturing preparation and regulatory submissions related to the stroke program.

Further updates are expected as Argenica progresses discussions with regulatory authorities and advances its clinical development activities.

Conclusion

Argenica Therapeutics (ASX:AGN) is continuing development activities for ARG-007 (xaranetide), with recent progress across stroke trial preparation, regulatory requirements and additional neurological research programs. The company completed FDA-requested safety assessments, received WHO confirmation of the drug candidate’s international name and reported cash reserves of $6.35 million as at 30 June 2026. Future company updates will provide further information on clinical trial development and regulatory progress.

FAQs

Q: What is Argenica Therapeutics’ ASX ticker code?

A:Argenica Therapeutics Limited is listed on the Australian Securities Exchange under the ticker code ASX:AGN.

Q: What is ARG-007 (xaranetide)?

A:ARG-007 (xaranetide) is Argenica’s lead neuroprotective drug candidate being developed for stroke and other neurological injuries.

Q: What clinical program is Argenica preparing for?

A:Argenica is preparing a targeted late-stage clinical trial for moderate to severe acute ischaemic stroke patients.

Q: What was Argenica’s cash position at 30 June 2026?

A:Argenica reported cash reserves of $6.35 million as at 30 June 2026.

Q: Does this article provide financial advice about Argenica Therapeutics?

A:No. This article is for general educational purposes only and does not provide financial advice, valuation, or any recommendation regarding securities.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.